ICCM Company Profile and Key Details

IceCure Medical Ltd last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.44. This means the shares are trading below this model’s fair value.

IceCure Medical Ltd (NASDAQ:ICCM) closed at $3.54 USD, losing -$0.11 (-3.01%) from the previous close of $3.65. The stock is currently mid-range between its 52-week high and low $2.12 and $42.00. With a market capitalization of about $7.97 million, IceCure Medical Ltd is classified as a micro-cap and shows higher-than-market volatility (beta ~1.54). Key stats such as the average daily volume over the past year has been around 3.37 million shares, volume is running light vs its 52-week average. Headquartered in Caesarea, HA, IceCure Medical Ltd operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Eyal Shamir, the company employs approximately 69 people and listed since August 26, 2021. Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process.

Our AI price prediction model suggests that IceCure Medical Ltd stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 49.15%, with price expected at $5.28 by July 27, 2026, within a range of $3.41 to $7.22 3-Month Outlook: Projected rise of 472.6%, reaching $20.27 by October 08, 2026, with a range of $20.13 to $20.42. 1-Year Outlook: Projected gain of 720.06%, with price at $29.03 by July 13, 2027, within a range of $31.37 to $33.85.

IceCure Medical Ltd (NASDAQ:ICCM) shares are flat 5.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows IceCure Medical Ltd trading at a premium to the broader market with a P/E of -0.51. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $2.66, suggesting -24.86% downside. Our AI forecast model points to short-term strength (49.15% over two weeks), a medium-term rise (472.6% over three months), and a longer-term gain (720.06% over one year), with expected trading ranges indicating moderate volatility.

IceCure Medical Ltd trades at a P/E ratio of -0.51, slightly below the S&P 500 average, with a price-to-sales ratio of 2.24 and a price-to-book ratio of 1.02 suggesting the stock is closer to book value. The P/FCF stands at -0.52, also above market averages.